Clinical TrialApr 28, 2026, 06:51 AM
ACRS: ATI-052 Phase 1a Positive Results; ATI-2138 Targets Lichen Planus
AI Summary
Aclaris Therapeutics announced positive full top-line results from its Phase 1a trial of ATI-052, an anti-TSLP/IL-4R bispecific antibody, demonstrating a potential best-in-class pharmacokinetic profile with an estimated half-life of 45 days, supporting up to three-month dosing. The trial showed robust target engagement and sustained inhibition of key inflammatory markers, with a favorable safety profile. Additionally, the company selected lichen planus as the lead indication for its selective ITK/JAK3 inhibitor ATI-2138, planning a Phase 2b basket study in H2 2026 for this unaddressed chronic inflammatory disease with a potential US market exceeding $1.0 billion.
Key Highlights
- ATI-052 Phase 1a trial showed positive full top-line results.
- ATI-052 estimated half-life of approximately 45 days, supporting up to 3-month dosing.
- ATI-052 demonstrated complete and sustained inhibition of TSLP-induced and IL-4 induced CCL17.
- ATI-052 Phase 1b results in asthma and atopic dermatitis expected H2 2026.
- Lichen planus selected as lead indication for ATI-2138.
- ATI-2138 Phase 2b basket study in LP to initiate H2 2026.
- Estimated US market for oral LP therapeutic exceeds $1.0B, up to $4.0B.